2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | CA$4.2B | CA$5.5B | CA$6.8B | CA$7.5B | CA$7.9B |
Cost of Revenue | CA$4B | CA$5B | CA$6B | CA$6.2B | CA$6.4B |
Gross Profit | CA$190M | CA$528M | CA$798M | CA$1.3B | CA$1.5B |
Gross Profit % | 4.5% | 9.5% | 12% | 17% | 19% |
R&D Expenses | CA$0 | CA$0 | CA$0 | CA$0 | CA$0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | -CA$995M | -CA$607M | -CA$311M | CA$45M | -CA$738M |
Dep. & Amort. | CA$1.2B | CA$1.4B | CA$1.5B | CA$1.5B | CA$1.6B |
Def. Tax | -CA$361M | -CA$106M | -CA$171M | -CA$197M | -CA$207M |
Stock Comp. | CA$38M | CA$46M | CA$55M | CA$125M | CA$105M |
Chg. in WC | CA$5.2M | -CA$46M | -CA$86M | CA$31M | -CA$18M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | CA$27M | CA$190M | CA$82M | CA$136M | CA$134M |
ST Investments | CA$0 | CA$0 | CA$0 | CA$0 | CA$0 |
Cash & ST Inv. | CA$27M | CA$190M | CA$82M | CA$136M | CA$134M |
Receivables | CA$867M | CA$1.1B | CA$1.1B | CA$1.1B | CA$1.3B |
Inventory | CA$57M | CA$82M | CA$84M | CA$98M | CA$108M |
GFL reported strong Q4 performance with 300 basis points of margin expansion and exceeded expectations in revenue, adjusted EBITDA, and adjusted free cash flow.
The company plans to deploy $325 million in incremental growth capital in 2025, primarily for EPR contracts, with cumulative investments in EPR expected to total $600 million by 2025.
GFL expects 2025 revenue growth of 6%-7% ($6.5-$6.55 billion) and adjusted EBITDA margin expansion of 100 basis points to 29.7%, driven by price-cost spread, self-help initiatives, and contributions from EPR and RNG projects.
The sale of the ES business is on track to close on March 1, with proceeds used to repay $3.75 billion in debt and fund $2.25 billion in share buybacks, reducing leverage to approximately 3x.
The company anticipates industry-leading organic growth and free cash flow conversion improvements, with a focus on M&A, share buybacks, and increased dividends as part of its capital allocation strategy.